Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Cellular immunotherapies, including T cell-based approaches like chimeric antigen receptor (CAR) T cells, have shown success in hematologic malignancies.
• Efficacy of adoptive cell therapies against solid tumors remains a significant challenge.
• Macrophages, innate immune cells with inherent anti-tumor functions, are emerging as promising candidates for solid tumor immunotherapy.

Purpose of the Study:

• To review the use of monocytes and macrophages in adoptive cell therapies for cancer.
• To focus on engineering strategies for macrophages, specifically chimeric antigen receptor macrophages (CAR-M).
• To discuss CAR design, production, and clinical considerations for CAR-M in treating solid malignancies.

Main Methods:

• Review of existing literature on macrophage-based immunotherapies and CAR engineering.
• Focus on strategies for designing and producing CAR-M for adoptive cell transfer.
• Analysis of clinical considerations and recent progress in CAR-M applications.

Main Results:

• Macrophages possess intrinsic effector functions crucial for combating solid tumors, including tumor site trafficking and phagocytosis.
• Engineering macrophages with CARs (CAR-M) enhances their targeting and anti-tumor capabilities.
• Recent advancements demonstrate the potential of CAR-M in preclinical and clinical settings for solid tumor treatment.

Conclusions:

• Engineered macrophages, especially CAR-M, represent a promising cellular immunotherapy for solid tumors.
• CAR-M leverage macrophages' innate effector functions, augmented by engineered targeting, to overcome limitations of current therapies.
• Further development and clinical application of CAR-M hold significant potential to expand the armamentarium against cancer.